目的．臨床病期Ⅲ期，Ⅳ期の非小細胞肺癌に対してシスプラチン（CDDP）＋ビノレルビン（VNB）＋マイトマイシン（MMC）の3剤併用化学療法を施行し，安全性と有効性について多施設による臨床検討を行った．方法．75歳以下の原発性非小細胞肺癌の初回治療例を対象にCDDP80mg/m~2（day1），MMC8mg/m~2（day1），非手術例はVNB25mg/m~2（day1，8），術前投与例はVNB20mg/m~2（day1，8）の投与を1コースとし，2コース以上の投与を目標とした．結果．登録症例は46例．39～72歳（平均61歳）で，臨床病期はⅢA期26例，ⅢB期10例，Ⅳ期10例．投与完遂は1～3（平均1.6）コースで，2コース以上の投与完遂は21例（46％）であった．Grade3以上の有害事象は，白血球減少13例（28％），血小板減少6例（13％），ヘモグロビン値減少4例（9％）のほか嘔気，食欲不振4例（9％），静脈炎2例（4％），腎不全1例（2％）であったが，すべて軽快して重篤な合併症には至らず治療関連死亡はなかった．抗腫瘍効果は評価可能例35例（76％）で，効果判定はPR13例，NC18イ軌 PD4例で奏功率は37％であった．結論．CDDP＋VNB＋MMC3剤併用療法は従来の標準的CDDP＋VDS＋MMC3剤併用療法と比べて奏功率，有害事象ともに遜色なく，非小細胞肺癌の併用化学療法の選択肢の一つに含めてよいと思われた．Objective. To evaluate the efficacy and tolerability of combination chemotherapy with cisplatin(CDDP), vinorelbine (VNB), mitomycin (MMC), we performed a clinical study in patients with previously untreated advanced non-small cell lung cancer (NSCLC). Study Design. Patients with clinical stage-Ⅲ or stage-Ⅳ and aged under 75 years old were entered in this study from 5 hospitals in the Saitama area. CDDP 80mg/m~2 and MMC 8mg/m2 were administered intravenously on day 1.in inoperable case VNB 25mg/m~2, and in pre-operative case VNB 20mg/m~2 administered intravenously on dayl and 8. The treatment was performed every 4 weeks and we planned to perform 2 courses or more. Results. Forty six patients were enrolled with a mean age of 61 (range 39-72) years old, and 26 were clinical stage-ⅢA, 10 were stage-ⅢB and 10 were stage-Ⅳ.The mean number of performed courses was 1.6 (range 1-3 courses), and there were 2leases with 2 or more courses.
展开▼
